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     INTRODUCTION 
  Malaria is a disease that is responsible for the deaths of over 
1 million people annually, largely affecting children < 5 years 
of age and pregnant women.  1   Deaths associated with the dis-
ease occur predominantly in sub-Saharan Africa; however, 
Asia, Latin America, and the Middle East are also affected to 
varying degrees.  2   The causative agent is a parasite belonging to 
the genus   Plasmodium  , with the majority of deaths occurring 
with   Plasmodium falciparum   infection. The parasite develops 
by asexual replication in the human host and sexual differen-
tiation in the   Anopheles   mosquito. 3   Sporozoites, transmitted 
to the human host by a mosquito bite; infect human liver cells 
giving rise to merozoites that invade circulating erythrocytes. 
The asexual blood stage of their life cycle involves the devel-
opment from ring stage parasites to trophozoites, which then 
mature into schizonts containing daughter merozoites. Upon 
schizont rupture, merozoites are again released into the blood 
stream, which infect new erythrocytes in a cycle that takes ~48 
hours to complete. Although a small proportion of the para-
sites differentiate into the sexual erythrocytic form, gameto-
cytes, which are taken up by the mosquito to undergo sexual 
development. It is the blood stage parasites that are responsi-
ble for the clinical manifestations of the disease, thus the focus 
of the most current drug discovery programs      . 
  Parasite resistance to anti-malarial drugs has become major 
impedance in the treatment of malaria. The chemical diversity of 
the recognized anti-malarial drugs to date is limited, consisting 
of four major classes of compounds, namely aminoquinolines, 
antifolates, artemisinin derivatives, and hydroxynapthoqui-
nones.  4   The concern, with respect to this limited chemical 
diversity, is that combination therapy of “new” drugs based 
on the known chemistry backbones will suffer from parasite 
resistance within a short period of time, caused by priming of 
the parasite by the “existing” drug. Sequencing of the   P. falci-
parum   genome has also demonstrated over 5,000 genes com-
prising a large number of diverse drug targets, many of which 
have yet to be characterized.  5   However, most of the current 
drugs to date interact with only a small selection of these drug 
targets including heme detoxification (chloroquine), folate 
metabolism, and the parasite’s mitochondria (atovaquone).  6  
There is, therefore, an urgent need for new anti-malarial drugs 
with chemical and biological diversity, to combat the increas-
ing parasite resistance to current drug treatments. 
  To optimize the potential of identifying compounds active 
against all possible parasite drug targets, a high-throughput 
screen measuring inhibition of parasite growth was required. 
The gold standard methods for parasite detection and drug 
susceptibility testing are considered to be microscopic exami-
nation of stained blood smears or a radiometric assay measur-
ing the incorporation of [  3  H]-hypoxanthine by the parasite.  7  
Other methods for detection of erythrocyte infection and drug 
susceptibility testing have also been developed using flow 
cytometry (YOYO-1 dye),  8   enzyme-linked immunosorbent 
assays (ELISA) measuring histidine-rich protein II,  9   ELISA 
and colorimetric assays measuring parasite lactate dehydro-
genase,  10,  11   and fluorescence-based microplate assays using 
DNA-binding dyes such as Hoechst,  12   PicoGreen, 13,  14   SYBR 
green I,  13,  15   and 4′,6-diamidino-2-phenylindole (DAPI).  16   A 
number of comparative studies have demonstrated the abil-
ity to detect   P. falciparum   at similar or greater sensitivity to 
microscopy and/or [  3  H]-hypoxanthine incorporation, and to 
yield similar IC  50   values for known anti-malarial compounds. 
 However, not all of these assay formats are suitable for high-
throughput screening (HTS) caused by factors such as cost, 
safety (radioactive waste disposal), assay stability and robust-
ness, equipment availability, and quality of data produced. 
  The fluorescent DNA dye-based assays are obviously adapt-
able to high-throughput applications as demonstrated by 
screening programs conducted in 384- and 1536-well for-
mats.  16,  17   These assays, however, measure total fluorescence 
intensity (TFI) outputs that are prone to potential interfer-
ences from the chemical entities being screened.  18   To  improve 
the sensitivity of these assays, Baniecki and others  16   had pre-
viously described the modification of a DAPI   P. falciparum  
growth assay for image-based analysis. 
  The efficiency of malaria drug discovery has been greatly 
enhanced by high content screening, the automated cell biol-
ogy process using optics, chemistry, biology, and image analy-
sis for rapid biological data acquisition.  19   The application of 
automated data acquisition and image analysis has already 
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been applied to the diagnosis of malaria using blood smears 
and light microscopy.  20–  22   The advantage of the image out-
put when compared with total fluorescence, is the ability to 
detect specific isolated areas of fluorescence (parasite detec-
tion) allowing the subtraction of all non-parasite-related back-
ground readings. This background subtraction compensates 
for fluorescence activity of compounds that could mask para-
site inhibition, thus potentially reducing false-negative rates. 
Although quenching compounds could yield false positives in 
both the imaging and total fluorescence assays, the effect of 
quenching compounds would be limited in the imaging assay, 
as the potential impact on the spot detection performed by 
the imaging software is far less than the impact on the actual 
fluorescence. 
  The protocol previously described for DAPI TFI and image 
analysis consisted of multiple centrifugation and reagent addi-
tion steps, which was not amenable for ultrahigh-throughput 
screening.  16   This article describes the optimization of a high-
throughput confocal imaging assay to identify anti-malarial 
compounds using DAPI for monitoring parasite growth. The 
simplification of the assay protocol, image acquisition, and 
data analysis allows for large numbers of compounds to be 
screened in a relatively short period of time. The HTS suit-
ability of this assay was initially demonstrated by screening a 
marine natural product library, where the outcomes obtained 
using confocal imaging were compared with the alternative 
whole well fluorescent intensity readouts. 
   MATERIALS AND  METHODS 
  Reagents.     Hypoxanthine, 1 M NaOH, D-sorbitol, chloro-
quine diphosphate salt, artemisinin, 10× phosphate buffered 
saline (PBS) solution, EDTA, 0.5 M solution, Tris-HCl, 
saponin (from Quillaja Bark), Triton X-100, Giemsa stain, 
paraformaldehyde, dimethylformamide, and Petri dishes were 
purchased from Sigma Aldrich (St. Louis, MO). Methanol 
and dimethylsulphoxide (DMSO) were obtained from Lab-
Scan Analytical Services (Gliwice, Poland). RPMI-1640 with 
L-Glutamine, Albumax II, and DAPI (“fluoroPure” grade) were 
purchased from Invitrogen (Carlsbad, CA). CellCarrier-384 
Imaging plates (clear, black, poly-D-lysine coated or tissue cul-
ture treated) were purchased from PerkinElmer (Waltham, MA)   . 
Human O+ erythrocytes were obtained from the Australian 
Red Cross Blood Service (agreement no: 09-05QLD-06). 
    P. falciparum   culture.     The 3D7 and Dd2 strains of   P. 
falci parum   were kindly provided by Dr. Kathy Andrews 
(Queensland Institute of Medical Research, Brisbane, 
Australia). Cultures were grown in accordance with the 
protocol initially described by Trager and Jensen  23   with some 
adaptations. The RPMI-1640 media with glutamine, sup-
plemented with 50 μg/mL hypoxanthine, 5 mg/mL Albumax 
II, and 5% O+ human erythrocytes was used for all aspects of 
the parasite culture and assay. For general culture, parasites 
were maintained in non-synchronous form between 0.1% and 
8% parasitemia in Petri dishes. Cultures were incubated in a 
Heraeus HeraCell 240 tri-gas incubator (Thermo Scientific, 
Waltham, MA) at 37°C using a gas mix of 5% CO  2 ,  5%  O 2 ,  and 
90% N  2  . Cultures were split every 48 hours by simple dilution 
(1:5 or 1:10) in growth media and hematocrit corrected with 
the addition of fresh erythrocytes. Parasite growth was moni-
tored using thin blood smears fixed in 100% methanol and 
stained for 10–20 min in Giemsa solution prepared in PBS. 
   Synchronization  of   P. falciparum   cultures.     Synchronized 
parasites were obtained using D-sorbitol treatment as 
described by Lambros and Vanderberg  24   and maintained 
in synchrony for up to 2 months. Basically, cultures containing 
> 3% ring stage parasites were harvested and centrifuged at 
600 ×  g  for 5 min (Heraeus Multifuge 3-SR, Thermo Scientific). 
The media was aspirated from the red blood cell (RBC) 
pellet and 5 mL of 5% (w/v) D-sorbitol added, the mixture 
swirled gently and left to stand for 5 min at room temperature. 
Tubes were then centrifuged, sorbitol removed, RBC pellet 
resuspended in media to the original volume and culture 
incubated under standard conditions for at least 7 hours before 
sorbitol treatment was repeated. Cultures were then split 1:2 
or 1:4 maintaining a 5% hematocrit. The next day, parasite 
growth was monitored using Giemsa-stained thin blood 
smears, If the % parasitemia was higher than 2%, then the 
cultures were further split to give a maximum parasitemia of 
1%. Forty-eight hours after the first sorbitol treatment, 4–8% 
ring stage parasites are typically observed and two sorbitol 
treatments (> 7 hours apart) were repeated. After at least two 
cycles of synchronization, cultures were used in the HTS assay 
and/or sorbitol treatment repeated for propagation of the 
parasite for an assay to be run 2 days later. In respect to this 
synchronization protocol and the   in vitro   loss of synchronicity 
within 24 hours, we believe the parasites are between zero 
and 24 hours old when used within the assay. 
   Preparation  of   P. falciparum   cultures for assay.     Parasite 
culture in early ring stage was harvested and centrifuged as 
previously described. The supernatant was removed and 
an equal volume of fresh growth media added to the cell 
pellet. Fifty microliters of the cell suspension was then added to 
950  μL of RPMI-1640 media and a cell count performed 
using a hemocytometer. From the RBC number, the actual 
% hematocrit was calculated, where 1% hematocrit solution = 
75  × 10  6   RBC/mL. A thin smear of the culture was then 
made and percentage parasitemia was calculated by counting 
at least 500 RBC (~6–8 fields of vision). Using the percentage 
parasitemia and actual hematocrit values, the culture was then 
diluted to 2% parasitemia in 0.75% hematocrit for the 3D7 strain 
and 3% parasitemia in 0.75% hematocrit for the Dd2 strain. 
   DAPI  high-throughput  anti-malarial  assay.    Library  plates 
of marine natural product extracts (250 μge/μL stock in 100% 
DMSO, μge = amount of biota used to prepare the extract) 
prepared at the Eskitis Institute, Griffith University were 
diluted 1/25 by adding 1 μL of stock extract using a 384-well 
head dispenser (MiniTrak Robotic Liquid Handling System, 
PerkinElmer) to 24 μL sterile water, in clear, sterile 384-well 
plates (BD Falcon, San Jose, CA). These plates were lidded 
and stored overnight at 4°C. Before use, the dilution plates 
were brought to room temperature and 25 μL of sterile water 
containing either 4% DMSO or 20 μM artemisinin (in 4% 
DMSO) as “in-plate” controls were added to the last two 
columns of the 384-well plates using an electronic multichannel 
pipette. 
  Five microliters (5 μL) of the diluted library plate (including 
in-plate controls) was then transferred into CellCarrier-384 
well Imaging plates (MiniTrak). Twenty-five microliters (25 μL) 
of assay media was dispensed into the plates using a Multidrop 
384 dispenser (Thermo Scientific) followed by the addition of 
20 μL of parasite preparation, The final assay well volume of 
50 μL therefore contained either 0.4% DMSO only (mini-
mum inhibition control), with 2 μM artemisinin (maximum 86 DUFFY AND AVERY
inhibition control) or 1 μge/μL natural product fraction, 2% 
or 3% parasitemia and 0.3% hematocrit. The plates were lid-
ded and incubated for 72 hours at 37°C/5% CO  2 .  Different 
parasitemias for 3D7 and Dd2 were initially used in this study 
to obtain similar assay windows, because initially it was found 
that when the assay was performed with Dd2 this always 
resulted in reduced spot numbers, thus a smaller assay win-
dow. The IC  50   value obtained for reference compounds did not 
alter with the higher parasitemia, and a comparable assay sig-
nal to background ratio was obtained. After continued evalu-
ation, the % parasitemia was subsequently changed to 2% for 
3D7 and Dd2 (and additional strains such as HB3, FCR3, and 
K1), because the parasite number is more relevant than the 
assay window, which is more a feature of the parasite strain 
growth rate. 
  After 72 hours incubation, all plates were brought to 
room temperature. Batches of 10 plates were then processed 
through the DAPI staining procedure in an overlapping for-
mat to increase throughput. Thirty × 384-well plates were 
run through the DAPI staining procedure at any one time. 
Using a 384-channel disposable tip dispensing head (Biomek 
FX, Beckman Coulter, Fullerton, CA), 30 μL of 1X PBS was 
added to all 10 plates, after which 60 μL of diluted supernatant 
was aspirated to waste. Thirty microliters (30 μL) of DAPI in 
permeabilization buffer (1X PBS, 0.01% Triton-X100, 0.001% 
saponin, 5 mM EDTA, and 0.5 μg/mL DAPI was then added 
to all 10 plates and left to incubate for 40 min at room tem-
perature in the dark. After incubation, 30 μL of excess DAPI-
permeabilization buffer was aspirated from the wells. The 
plates were stacked and left at room temperature in the dark 
for at least 4 hours or until the assay window was greater than 
10-fold. All the additions and aspirations using the Biomek 
FX were optimized to minimize any disturbance of the RBC 
cell layer and reduce aerosol formation. Waste was immedi-
ately evacuated into a lidded container with 500 mL of con-
centrated bleach. 
  After incubation, the plates were then loaded onto the 
Twister II Microplate Handler (PerkinElmer) and imaged on 
the Opera confocal microplate imaging reader (PerkinElmer) 
using the following settings; image size 0.430 × 0.345 mm  2 ,  20X 
water objective with a 405-nm excitation line and 420–490-nm 
band pass emission filter, laser power of 1,870 μW, and camera 
exposure times of 80 msec. A single image per well was taken 
1 μm above the bottom of the plate within the erythrocyte cell 
layer. After reading on the Opera, the plates were also mea-
sured on a Victor  2   microplate reader (PerkinElmer) at 355 
nm  exc /460  nm em   to obtain total well fluorescence intensity. 
   Data  analysis.     Image analysis was performed with the 
Acapella version 2.0 data processing software (PerkinElmer) 
using a spot detection algorithm. First, local pixel intensity 
maximums were detected over the entire image of each well 
(0.430 × 0.345 mm  2  ). A circle, four pixels in radius, was drawn 
around the intensity maximums and designated as a spot. The 
spots were then classified as real spots, on the basis of two 
parameters. Contrast of the maximum fluorescence intensity 
of the spot with the surrounding pixels in the circle and 
SpotToCell Intensity, which was used to compare maximum 
spot intensity to the background intensity found over the 
whole image. For this assay a contrast of 0.5 and SpotToCell 
Intensity of 4 was used. 
  Converted data was then exported as the number of spots 
per image to calculate percentage inhibition values of treated 
wells (T) using the minimum inhibition control (0.4% DMSO, 
Min) and maximum inhibition control (2 μM Artemisinin, 
Max) as shown in Eq. (1).
      %   inhibition   =   100   −   (  (  T   −   Max  )  /  (  Min   −   Max  )   ×   100  )  .        
 The  IC 50   values were calculated from dose response curves 
generated using GraphPad Prism version 4.0 (Hallogram 
Publishing, Aurora, CO). 
    RESULTS 
    Establishment of RBC number: percentage hematocrit 
relationship.     Hematocrit in medical fields is defined as the 
percentage, by volume of packed RBCs, in a given sample of 
blood after centrifugation. The % hematocrit is a standard 
term used in Malaria culture protocols and refers to the 
percentage of packed RBC in the culture, based on the RBC 
pellet, after centrifugation, being 100% hematocrit. For exam-
ple 5% hematocrit is 0.5 mL of compacted RBC added to 
9.5 mL of culture media. As this term is used in almost all 
protocols for Malaria culture we have maintained its use for 
comparison purposes. However, the actual number of RBC 
per ml of culture in a standard Malaria culturing protocol can 
be quite variable caused by multiple factors such as cell lysis 
caused by parasite replication, disturbance of compacted RBC 
suspension, and pipetting accuracy of 100% compact RBC. 
Throughout the initial development of the DAPI-imaging 
assay, significantly varied optimum and signal to background 
(S/B) ratio responses were observed. Although we routinely 
determined the % parasitemia by Giemsa-stained blood 
smears, we worked on a supposed hematocrit value of 5% 
for the culture and made all dilutions based on this value. At 
this point, we postulated that the total number of RBC in a 
well could have an effect on the detection of parasite infected 
RBC, and thus assay reproducibility. 
  To standardize this parameter, and thus the reproducibility 
of the assay, an RBC number value that equates to 1% hema-
tocrit was established. From five individual tubes of 100% 
erythrocyte preparations, a sample volume was diluted in assay 
media to give a 2.5% hematocrit. To ensure accuracy, this was 
performed using Gilson micropipettes rather than serological 
pipettes. Each tube was then further diluted 1:200 and a cell 
count performed using a hemocytometer. 
  The average cell number and % coefficient of variation 
(% CV      ) was calculated for the five independent RBC prep-
arations, taking into account the 1:200 dilutions of the 2.5% 
hematocrit solutions. The average cell number for 2.5% hema-
tocrit was then converted to the number of erythrocytes as 
standard in 1% hematocrit. It was determined that an average 
of 187.5 × 10  6   RBC/mL represented 2.5% hematocrit (6.3% 
CV obtained). Therefore, 1% hematocrit has an average of 
75 × 10  6   RBC/mL. This concentration was subsequently used 
for preparation of parasite cultures for screening. During rou-
tine culture maintenance the value of % hematocrit is still 
used, but when preparing the culture for use in the screening 
assay the number of RBC/mL is measured using a hemocy-
tometer and subsequent conversion to its % hematocrit value 
is made for comparison with other assay protocols in the lit-
erature. The accurate % hematocrit value in conjunction with 
% parasitemia, determined by Giemsa smear, can be used to 
determine the actual total number of RBC in the assay well, 
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effect can be seen in the Results section:   Effect of percentage 
hematocrit on parasite detection ). 
      Optimization of image acquisition using the Opera Con-
focal Image Reader.     In this assay, unlike most mammalian 
cell imaging assays, we are not imaging a single monolayer of 
cells. Each well contained homogeneous layers of compacted 
RBCs in all possible orientations. During the staining process, 
a minor degree of disturbance to the compacted cell layer 
occurs, resulting in areas of less compacted cell densities, which 
may result in poor interwell precision within the assay. 
  To optimize image acquisition during assay development 
and HTS, a “z-stack” of images was taken using the Opera 
software to determine the optimum focal plane for imag-
ing, but more specifically for assay reproducibility. This was 
achieved by imaging CellCarrier plates containing minimum 
(0.4% DMSO) and maximum (2 μM artemisinin) inhibition 
controls using 3D7 strain parasites at 2% parasitemia and 
0.3% hematocrit. Images of the cells were captured using set-
tings previously described (Materials and Methods section: 
  DAPI HTS anti-malarial assay  ) of wells in 1.00 μm intervals, 
starting from −1.00 μm (the distance the image is captured 
from the liquid-solid interface layer detected by the autofo-
cus laser). Control well images were examined by eye and the 
Acapella spot detection algorithm was used to obtain the opti-
mum focus height for the greatest differentiation between the 
control wells. The actual focus height had only minimal effect 
on the detection of spot numbers but we found that the lower 
the read height, the greater the fluorescence measurement. 
This was most likely caused by less dissipation of the laser 
stimulation through the RBC layers. These parameters were 
then applied to control plates containing at least 96 minimum 
and maximum control wells for evaluation of Z′. This evalua-
tion of focus height was used numerous times throughout the 
development of the assay and was found to be consistent at a 
1μm focus height, resulting in Z′ values of 0.5 and above. 
  A reference image was also used to correct for excitation 
intensity differences across the well as the laser excitation is 
brightest in the center. The reference image was composed of 
one fluorescent dye excited using the 405-nm laser, which was 
scanned before the data images      . Upon detecting fluctuations 
in emission intensity across the well, correction factors were 
applied automatically to subsequent images to reproduce the 
effect of even excitation. Laser power and camera exposure 
times were set to ensure fluorescence counts of between 300 
and 3,000 were obtained (the optimum operating range of the 
charge-coupled device). For these assays, a laser power of 1,870 
μW and camera exposure of 80 ms was used. An example of con-
trol images containing various concentrations of artemisinin with 
corresponding spot detection analysis is shown in (  Figure 1  ). 
        Effect of percentage hematocrit on parasite detection.    The 
effect of percentage hematocrit on the detection of parasite 
(number of spots) was evaluated by examining the same 
number of infected RBC in different total numbers of non-
infected RBC. This investigation was performed after the 
standardization of the RBC number to percentage hematocrit 
relationship and shows the effect of % hematocrit (or number 
of RBC/mL) on parasite detection. 
  A culture containing Dd2 strain parasites was diluted to dif-
ferent numbers of infected RBC and the hematocrit altered 
to give different hematocrit percentages. Each variable was 
tested in 16 wells containing both minimum and maximum 
inhibition control wells. 
 Increasing the number of non-infected erythrocytes resulted 
in a decrease in the signal (number of spots) obtained for the 
same number of infected erythrocytes (  Figure 2  ). This is a con-
sequence of the non-infected and infected cells competing for 
the detection/imaging area on the Opera. This effect is of con-
siderable importance in this imaging assay, as any variation in 
the non-infected RBC number can increase or decrease the 
signal for the same number of parasites. The same effect may 
possibly have resulted because of variation in parasite growth; 
however, data obtained using cultures of very high para-
sitemia, with a minimal settling period before the plates being 
processed through the DAPI staining protocol, also demon-
strated the same trend (data not shown). 
    Effect of the permeabilization buffer and paraformaldehyde 
fixation on parasite staining, linearity, and assay precision.  
  Optimization of the plate processing steps required for image 
analysis, previously recommended by Baniecki and others  16  
initially involved elimination of time-consuming centrifuga-
tion steps while retaining the fixation of cells with para-
formaldehyde and the use of Tris-HCl permeabilization 
buffer. However, this resulted in a diminished assay precision 
(  Figure 3A  ). Visual inspection of plates during processing 
suggested excessive erythrocyte lysis was a contributing factor. 
The Tris-HCl permeabilization buffer (20 mM Tris-HCl pH 
7.5, 5 mM EDTA, 0.001% Triton-X100, and 0.001% saponin) 
and an alternative PBS permeabilization buffer (PBS pH 7.4, 
5 mM EDTA, 0.01% Triton X-100, and 0.001% saponin) were 
therefore assessed for ability to induce cell lysis. 
    Red blood cells were diluted to 1% hematocrit with either 
PBS or Tris-HCl permeabilization buffer, incubated at room 
  Figure   1.        Representative images of wells containing the 3D7 par-
asite and varying concentrations of artemisinin. Images obtained on 
the Opera with the number of spots determined using the Acapella 
software with a spot detection algorithm. Relative % inhibition values 
were  also  calculated.    
  Figure   2.        Comparison of minimum inhibition (0.4% DMSO) and 
maximum inhibition (2 μM artemisinin) control responses at vary-
ing concentrations of Dd2 parasites (infected red blood cells) using 
0.25%, 0.5%, and 1.0% hematocrit. Each point represents the mean ± 
SEM of eight wells. Each data point represents the mean ± SEM of 
16  wells.    88 DUFFY AND AVERY
temperature for 10 min, and centrifuged at 600 ×   g   for 2 min. 
The supernatant was removed and Giemsa-stained thin blood 
smears were prepared from the resultant cell pellet and ana-
lyzed under a light microscope to determine the degree of cell 
lysis. It was clearly demonstrated by the Giemsa smears, and 
observed readily by eye, that the use of the Tris-HCl buffer 
resulted in almost total RBC lysis where no intact RBC could 
be visualized in the Giemsa smear. In comparison, intact RBC 
was observed in the presence of PBS buffer. 
  To further improve the quality and efficiency of the assay, 
the effect of paraformaldehyde fixation on linearity of fluo-
rescent staining and assay precision was also assessed. Plates 
containing Dd2 strain parasites (0.3% hematocrit, 0–4% para-
sitemia) added to six minimum and six maximum inhibition 
control wells were processed using either Tris-HCl or PBS per-
meabilization buffer, with or without paraformaldehyde fixa-
tion. The latter process involved the addition of 30 μL of 7% 
paraformaldehyde to the plate, followed by 1-hour incubation 
at room temperature before aspiration of 60 μL of well vol-
ume and addition of stain. 
  In the absence of paraformaldehyde fixation, 30 μL of assay 
volume was aspirated directly from the well before staining. 
This, however, while eliminating a processing step in the assay, 
caused plate edge effects that were attributed to the disruption 
of the cell bed during the aspiration step and variation of well 
volumes caused by evaporation during the 72-hour incuba-
tion period. Subsequently, the addition of 30 μL of paraform-
aldehyde was replaced with 30 μL of PBS buffer and 60 μL of 
supernatant aspirated before staining, which reduced the edge 
effects previously observed. It is likely that the buffer addition 
in the absence of fixation performs two roles. First, it equals 
out the volumes in all the wells allowing accurate aspiration, 
minimal disruption/disturbance to the cell bed, and standard-
izes the remaining well volumes. Second, the addition of buffer 
provides a wash step that removes potentially interfering com-
pounds in the DAPI staining or measurement. 
  The results (  Figure 3B–D  ) indicate that the use of PBS 
buffer without paraformaldehyde fixation produced supe-
rior assay precision and performance. The linear relationship 
between percentage parasitemia and spot number when using 
PBS-based permeabilization buffer, showed that the param-
eters and settings selected for use in the algorithm for spot 
detection (size, shape, and fluorescence of malaria parasites) 
allow a direct measurement of parasite number. 
  From this experiment the final % hematocrit and % par-
asitemia were chosen for each parasite strain based on the 
number of spots obtained and the Z′. 
      Optimization of aspirating and dispensing using Biomek 
FX.     Processing of plates for the addition of DAPI after 
incubation was optimized using the Biomek FX liquid han-
dling system. All protocols used on the Biomek FX were 
optimized for minimum aerosol production and disturbance 
of the erythrocyte layer. 
  The assay can also be run in a homogeneous format with 
stain and permeabilization buffer added directly to the wells, 
post incubation, with no aspiration required. The plates pro-
cessed in this way result in comparable IC  50   values for chlo-
roquine and artemisinin when measured on the Opera, but 
could not be measured on the Victor  2   microplate reader as the 
residual media and stain background is too high (i.e., no signal 
window observed). The effect of running the assay in a homo-
geneous format on false positive or negative rates had not 
been fully evaluated at the writing of this article. 
      Effect of time on DAPI staining before measurement on 
maximum and minimum control responses and reference 
compound IC  50   values.     As the Opera takes ~10 min to load, 
image, and unload a plate, the impact of different staining 
times on the assay performance was assessed. Processing of 
large plate sets through the DAPI staining process without 
timing restrictions with respect to imaging would greatly 
facilitate HTS efficiency. To determine the effect of incubation 
time following staining on imaging, 48 plates were run through 
the HTS DAPI-imaging assay using 3D7 strain parasites. After 
30 min incubation with DAPI in the dark, 30 μL of the total 
50 μL DAPI stain was removed, leaving 20 μL of stain (0.3 
μg/mL DAPI). The plates were then measured on the Opera. 
Forty-three plates were measured over an 8-hour period, and 
five plates were left overnight and measured the next morning. 
The Opera data was converted to number of spots and the 
mean ± SEM internal plate control values (16 maximum 
  Figure   3.        Comparison of permeabilization buffer and paraformaldehyde fixation on minimum inhibition response (solid squares), maximum 
inhibition response (solid triangles), and Z’ factor (red circles) of   Plasmodium falciparum   Dd2 strain parasites at varying parasitemia and 0.3% 
hematocrit. Combinations of Tris-HCl buffer with fixation (  A  ), Tris-HCl buffer without fixation (  B  ), phosphate-buffered saline (PBS) buffer with 
fixation (  C  ), and PBS buffer without fixation (  D  ) are shown. Where a linear relationship between parasitemia and minimum inhibition response 
was observed, linear regression (dotted) line and r  2   values  were  included.    89 NOVEL 384-WELL ANTI-MALARIAL IMAGING ASSAY VALIDATED FOR HIGH-THROUGHPUT SCREENING
and 16 minimum control wells per plate) plotted against 
plate number, which is equivalent to time (  Figure 4A  )      . An 
increase in maximum spot number is seen for plates incubated 
overnight in relation to those imaged on the day of staining. 
However, if the data is analyzed for S/B ratio the average 
ratio has only increased from 20 to 22 for those left overnight. 
Because of this very minor increase in S/B ratio it is felt 
that the increase in spot number for the maximum response 
is caused by continued permeabilization of the RBC by the 
saponin and Triton X-100, which allows for more parasites to 
be stained. These results showed that the assay plates, once 
processed for DAPI staining, can be kept for up to 48 hours 
at room temperature ready for imaging without any effect on 
precision or activity (only 24 hours shown). For longer storage, 
sealing and storing at 4–8°C is possible. 
    A full control plate was also included within these 48 plates 
and measured after 24 and 48 hours, post-DAPI incubation 
and aspiration. The IC  50   concentrations of artemisinin at both 
time points were comparable (  Figure 4B  ), however a slight 
drop in Z’ values from 0.6 at 24 hours to 0.52 at 48 hours was 
observed, most likely associated with some slight edge effects. 
      Evaluation and validation of the anti-malarial imaging 
assay for HTS.     An HTS campaign was run using the anti-
malarial imaging assay consisting of 336, 384-well assay plates 
containing fractionated marine natural products. These plates 
were screened against both the 3D7 and Dd2 strains of   P. 
falciparum   during seven consecutive screening days. Each 
day, 100 plates were processed through the imaging assay in 
batches of 50 consisting of 48 fraction plates and two control 
plates. Each control plate consisted of a 16-dose concentration 
curve for artemisinin and chloroquine (4 wells per dose each), 
128 × 0.4% DMSO wells and 128 × 2 μM artemisinin wells. 
For comparison, the plates were also measured for TFI on the 
Victor  2    microplate reader (355 nm  exc /460  nm em ). 
  In-plate control values within a representative 50-plate 
batch run (3D7 strain) were plotted (  Figure 5A  ) and showed 
stability of the assay window with minimal intraplate varia-
tion. The average response of in-plate controls between 
screening days obtained using image analysis or TFI measure-
ment with calculated S/B ratios were also compared (  Figure 
5B–D  ). The first 2 days of screening were measured on the 
day of staining, whereas the later screening days were left for 
at least 8 hours after staining before image acquisition. This 
is reflected in the apparent variation in screening day versus 
number of spots graph (  Figure 5B  ), but the comparable signal 
to background data (  Figure 5D  ) indicates a reproducible assay 
window through screening days. The S/B ratio obtained with 
image analysis was on average over two times greater than that 
observed using TFI readouts. These results also suggest that 
the total fluorescence measurements obtained by the Victor  2  
are more susceptible to slight variation in assay volumes, as an 
instrumentation error involved with DAPI permeabilization 
buffer addition and aspiration on Day 6 significantly reduced 
the TFI S/B ratios; however, measurement on the Opera still 
retained only a slightly reduced S/B ratio. 
  The  IC 50   values of artemisinin and chloroquine were also 
calculated using results obtained from control plates for each 
screening day, measured on both the Opera and Victor  2   for 
3D7 (  Table 1  ) and the Opera alone for Dd2. The average IC  50  
values for artemisinin and chloroquine were also compared 
for both the chloroquine-sensitive parasite strain, 3D7 and 
chloroquine-resistant  strain,  Dd2  ( Table  2           ). Two  whole  control 
plates containing 16-point dose response curves for chloro-
quine and artemisinin (4 wells per dose) were run each screen-
ing batch. The results show comparable IC  50   values using both 
image-based analysis or TFI readouts. In anti-malarial com-
pound screening assays described elsewhere, artemisinin can 
be seen to be significantly more active than chloroquine in 
some instances,  25   whereas in others they are much the same.  16  
The reason for these differences is not clear, but we believe 
they could be caused by the age and/or stage of the parasite 
at the start of the assay, the strain of parasite used (average 
  Figure   4.        Stability of signal after 4′,6-diamidino-2-phenylindole (DAPI) staining of assay plates containing the 3D7 strain of parasite. The 
response to in-plate controls of plates (mean ± SEM of 16 wells) read up to 24 hours after DAPI staining is shown in (  A  ). Dose response curves of 
artemisinin read 24 and 48 hours after DAPI staining (  B  ). Each point represents the mean ± SEM of 4 wells.       90 DUFFY AND AVERY
cycle time), and the assay incubation time. The assay described 
within this article incorporates two cycles of proliferation 
based on the age of the parasite used at the start of the assay 
(0 to 24 hours old), the 72 hours of incubation and loss of syn-
chronicity throughout the incubation. The assay identifies 
both fast and slow acting compounds but does not distinguish 
between them. 
 The initial HTS of the marine natural product library yielded 
1,071 fractions of interest. Greater than 80% of the HTS frac-
tions confirmed activity at retest, which was performed in a 
5-point dose response against both 3D7 and Dd2 parasite 
strains. Of these, 727 fractions from 154 independent marine 
biota passed cytotoxicity testing against HEK-293 mammalian 
cells for evaluation of their selectivity index. A number of the 
compounds isolated have been published,  26,  27   whereas others 
have formed the basis of ongoing projects. 
      Advantage of anti-malarial imaging assay compared with 
TFI measurement.     As previously highlighted the anti-malarial 
imaging assay was developed in part to overcome potential 
  Figure   5.        Evaluation of in-plate minimum inhibition (0.4% dimethylsulphoxide [DMSO]) and maximum inhibition (2 μM artemisinin) con-
trols during a 7-day screening run using 3D7 parasites. In-plate controls (mean ± SEM of 16 wells) within a 48-plate batch as measured with image 
analysis were compared (  A  ). Average in-plate control values (mean ± SEM of 256 wells) for each screening day as measured using spot detection 
image analysis (  B  ) or total well fluorescence (  C  ). Average signal-to-background ratio for each screening day using both detection methods were 
also calculated (  D ) .    
  Table  1 
    Comparison of average IC  50   values of positive controls calculated 
from image analysis or total well fluorescence during a 7-day 3D7 









Plate 1 Plate 2 Plate 1 Plate 2
Chloroquine 1 28.1 222.3 22.6 25.7
2 19.9 19.8 20.0 18.9
3 28.5 26.0 21.9 32.0
4 25.5 25.3 22.5 20.8
5 39.8 24.7 27.6 34.6
6 19.6 16.6 18.4 18.9
7 29.9 – 23.0 25.3
Artemisinin 1 22.1 17.8 20.6 20.4
2 13.6 12.4 15.2 13.2
3 22.0 23.0 22.7 22.0
4 23.7 32.0 20.8 24.5
5 37.2 23.6 27.9 22.4
6 11.7 12.6 11.3 11.2
7 14.4 – 30.8 20.3
    *      Two whole plate controls containing chloroquine and artemisinin concentration curves 
(4 wells per dose) were run each day.   
  Table  2 
    Comparison of average IC  50   values of positive controls calculated 
from image analysis during a 7-day screening run for both 3D7 and 
Dd2  parasites *   
Control compound Screening day
IC  50   (nM)
3D7 spot analysis Dd2 spot analysis














    *      Two whole plate controls containing chloroquine and artemisinin concentration curves 
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interferences observed with TFI readings. The advantage of the 
imaging-based assay was particularly highlighted when dose 
response curves were analyzed for a compound isolated from 
a marine organism. A characteristic sigmoidal dose response 
curve was obtained from results using image analysis ( Figure 6 ), 
whereas using TFI measurement, the curve did not plateau at 
the higher compound concentrations, preventing accurate IC  50  
value calculations. 
    The improved sensitivity of the image-based assay could be 
attributed to the limited available three-dimensional space 
where the image is captured (1 μm above the bottom of the 
well) minimizing the detection of fluorescent or quenching 
molecules. In addition, the parameters used for image capture 
and analysis are set to specifically detect fluorescent particles 
with respect to the size, shape, and fluorescence of malaria 
parasites. Conventional fluorescence assays, however, cap-
ture total fluorescence within a well, which would encompass 
any background fluorescence or fluorescence quenching com-
pounds. This interference in the total fluorescence intensity 
measurement could be responsible for false negatives when 
screening at a single dose and applying a single “active” cutoff. 
This difference in IC  50   curve shape has been seen for a num-
ber of isolated compounds. This advantage was also reported 
in a cross-laboratory study by Guiguemde and others  28   where 
this imaging assay was used in conjunction with two TFI-based 
assays to screen a panel of compounds, which demonstrated 
activity in a TFI HTS campaign. Both TFI assays were found 
to have problems with obtaining IC  50   values for some of the 
compounds. However, the imaging assay was able to circum-
vent the possible compound interference resulting in IC  50   val-
ues being obtained for all of the compounds. 
    DISCUSSION 
  In the search for new anti-malarial compounds to combat 
drug resistance, an HTS program was proposed. Evaluation of 
various   P. falciparum   growth inhibition assay formats indicated 
that for HTS purposes, the use of a fluorescent nucleic acid 
dye to monitor parasite growth would be the most amenable. 
 The   P. falciparum   growth assay using DAPI was previously 
developed using both TFI readouts and image-based analysis. 
As image-based analysis was preferred to improve data qual-
ity by eliminating potential interferences caused by fluorescent 
or quenching compounds, the original DAPI assay was further 
modified and optimized to significantly improve throughput, 
while maintaining assay precision and the magnitude and lin-
earity of the fluorescent signal. Specifically, this was achieved 
by altering the assay buffer components, eliminating fixation 
and centrifugation steps, and optimization of RBC concentra-
tion (hematocrit). 
  Using these conditions, the assay was initially validated 
by screening a marine natural product library. The results 
obtained show that the response of minimum and maximum 
control wells was maintained up to 48 hours after DAPI 
staining with stability of the response for control wells con-
sistent within screening batches and between screening days. 
Although we have also shown that plates may be measured 
using both image-based analysis and TFI, the advantage of the 
assay read on a confocal plate imager is evident in the supe-
rior signal-to-noise ratio and stability of the signal in response 
to assay variation. In addition, we have subsequently demon-
strated that it is possible to run more than three times as many 
plates per screening run by further optimization of plate pro-
cessing and measurement, despite the longer plate reading 
times of a confocal plate imager when compared with a stan-
dard microplate reader. 
  The ability to store and review the images also confers a 
distinct advantage to TFI measurements, whereby a more 
detailed interpretation may be applied to indicate the para-
site stage at which growth was stopped. Parasite stage specific-
ity experiments often include initial mode of action studies of 
lead anti-malarial compounds, however, these experiments are 
time consuming and low throughput. This is still under inves-
tigation but indications within our laboratory, and elsewhere, 
are that the parasites are more or less fluorescent at different 
stages of their life cycle caused by different levels of DNA.  29  
Using specific algorithms set to detect size and fluorescence of 
objects within the image, stage specificity information could 
be obtained during the initial screening process or, more likely, 
during assays performed specifically for stage effect during 
IC  50   determination. 
  Subsequently, since screening of this initial marine natural 
product library, a large number of chemical libraries ranging 
in size from 5,000 to 500,000 compounds have been screened. 
The source of the libraries has been diverse including large 
and small pharmaceutical and biotech companies and aca-
demic laboratories. As expected the hit rate and percent con-
firmation has varied depending upon the chemical diversity 
and configuration of the library, and the HTS concentration      . 
Since the initial development of the imaging assay, it has been 
estimated that well over 3 million data points have now been 
screened. The result of these screening campaigns has been the 
identification of thousands of compounds, which have pro-
gressed through to accurate IC  50   determination against the 
parasite and measurement of their selectivity index against 
mammalian cells, resulting in the selection of lead compound 
series for progression into the next stages of the malaria drug 
discovery process. The performance of this assay has recently 
been compared with results obtained by other anti-malarial 
assays in a study by Guiguemde and others  28   where it gave 
good reproducibility for compounds over a wide potency 
range. In conclusion, this work has described the development 
and validation of a high-throughput, robust, and sensitive 
  Figure   6.        Comparison of dose response curves of a representa-
tive marine natural product against 3D7 parasites as measured using 
spot detection image analysis (solid squares) or total well fluorescence 
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anti-malarial assay designed specifically for image-based anal-
ysis, with significant advantages over current anti-malarial 
screening technologies. 
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